Gilead Sciences Inc.'s (GILD) lowered its 2010 net product sales projection to a range of $7.4 billion to $7.5 billion, citing the "estimated impact of U.S. Healthcare Reform."

The Foster City, Calif., drug maker previously projected 2010 net product sales of $7.6 billion to $7.7 billion, translating to growth of 17% to 19% for the year.

Wall Street currently projects total revenue for the year of $8.28 billion, which includes revenue from royalties, contracts and other sources, according to Thomson Reuters.

In 2009, the company reported product sales of $6.47 billion and revenue of $7.01 billion.

-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Gilead Sciences Charts.